文献速递心律失常冠心病

房颤合并缺血性卒中出血转化患者直接口服抗凝药早期与晚期启动:ELAN随机试验预设亚组分析

Early Versus Late Initiation of Direct Oral Anticoagulants After Ischemic Stroke in People With Atrial Fibrillation and Hemorrhagic Transformation: Prespecified Subanalysis of the Randomized Controlled ELAN Trial.
PubMed 文献 · Circulation · 2024-05-16

该研究为ELAN试验的事后分析,评估出血转化(HT)是否改变早期与晚期启动直接口服抗凝药的治疗效应。1970例参与者中247例(12.5%)存在HT,主要复合终点在HT与无HT者中均无显著差异,但PH亚组早期治疗可能与90天功能结局恶化相关。

要点

  • 合并HT者早期与晚期启动DOAC的主要复合终点风险差为-2.2%(95%CI -7.8%至3.5%),无显著异质性。
  • PH亚组早期治疗90天不良功能结局风险差为25.1%(95%CI 0.2%至50.0%),提示可能恶化功能结局。
  • 有无HT者症状性颅内出血数量相同,未观察到早期启动的安全性信号。

核心结论

  • 在合并与不合并HT的房颤缺血性卒中患者中,未发现早期与晚期启动DOAC存在主要治疗效应异质性或安全性担忧。
  • 但在PH患者中,早期启动DOAC可能恶化功能结局。

研究设计与样本

  • ELAN随机对照试验的预设亚组事后分析,共纳入1970例参与者。
  • HT依据随机前影像由核心实验室判读,分为出血性梗死(HI)1型114例、HI 2型77例、脑实质出血(PH)1型34例、PH 2型22例。

主要发现

  • 247例(12.5%)存在HT。
  • 主要复合终点(30天内复发性缺血性卒中、症状性颅内出血、大出血、系统性栓塞或血管性死亡)的校正风险差(早期 vs 晚期):HT者-2.2%(95%CI -7.8%至3.5%),HI者-4.7%(95%CI -10.8%至1.4%),PH者6.1%(95%CI -8.5%至20.6%),无HT者-0.9%(95%CI -2.6%至0.8%)。
  • 90天不良功能结局(mRS 3-6)的校正风险差:HT者11.5%(95%CI -0.8%至23.8%),HI者7.4%(95%CI -6.4%至21.2%),PH者25.1%(95%CI 0.2%至50.0%),无HT者-2.6%(95%CI -7.1%至1.8%)。
  • 有无HT者症状性颅内出血数量相同。

临床怎么用

  • 对于房颤缺血性卒中合并HT的患者,早期启动DOAC未显示明确安全性担忧,但PH患者需警惕功能结局恶化风险。
  • 临床决策应结合HT亚型(尤其PH)个体化评估早期抗凝的获益与风险。

局限性

  • 本研究为ELAN试验的事后分析,HT亚组样本量较小(尤其PH亚组),结果需谨慎解读。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether hemorrhagic transformation (HT) modifies the treatment effect of early compared with late initiation of direct oral anticoagulation in people with ischemic stroke and atrial fibrillation is unknown. METHODS: This is a post hoc analysis of the ELAN trial (Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation). The primary outcome was a composite of recurrent ischemic stroke, symptomatic intracranial hemorrhage, major extracranial bleeding, systemic embolism, or vascular death within 30 days. Secondary outcomes were the individual components, 30- and 90-day functional outcome. We estimated outcomes based on HT, subclassified as hemorrhagic infarction (HI) or parenchymal hemorrhage (PH) on prerandomization imaging (core laboratory rating) using adjusted risk differences between treatment arms. RESULTS: Overall, 247 of 1970 participants (12.5%) had HT (114 HI 1, 77 HI 2, 34 PH 1, 22 PH 2). For the primary outcome, the estimated adjusted risk difference (early versus late) was -2.2% (95% CI, -7.8% to 3.5%) in people with HT (HI: -4.7% [95% CI, -10.8% to 1.4%]; PH: 6.1% [95% CI, -8.5% to 20.6%]) and -0.9% (95% CI, -2.6% to 0.8%) in people without HT. Numbers of symptomatic intracranial hemorrhage were identical in people with and without HT. With early treatment, the estimated adjusted risk difference for poor 90-day functional outcome (modified Rankin Scale score, 3-6) was 11.5% (95% CI, -0.8% to 23.8%) in participants with HT (HI: 7.4% [95% CI, -6.4% to 21.2%]; PH: 25.1% [95% CI, 0.2% to 50.0%]) and -2.6% (95% CI, -7.1% to 1.8%) in people without HT. CONCLUSIONS: We found no evidence of major treatment effect heterogeneity or safety concerns with early compared with late direct oral anticoagulation initiation in people with and without HT. However, early direct oral anticoagulation initiation may worsen functional outcomes in people with PH. REGISTRATION: URL: http://www.clinicaltrials.gov; Unique identifier: NCT03148457.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Rohner, Kneihsl, Goeldlin, et al. Early Versus Late Initiation of Direct Oral Anticoagulants After Ischemic Stroke in People With Atrial Fibrillation and Hemorrhagic Transformation: Prespecified Subanalysis of the Randomized Controlled ELAN Trial. Circulation. 2024. PMID: 38753452. doi:10.1161/CIRCULATIONAHA.124.069324

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。